T he potential of gene therapy to target the expression of therapeutic genes to the desired target cells makes it particularly attractive for cancer treatment. However, although there are vectors available with high transfection efficacy in cell culture, 1 -4 efficient and target -specific gene delivery in vivo is still the major challenge in gene therapy. In vivo gene delivery has to overcome additional obstacles such as anatomical size constraints and nonspecific interactions with biological fluids and nontarget cells. Recently, we have developed surface -shielded transferrin -polyethylenimine ( Tf-PEI )-based gene delivery systems that are able to target reporter gene expression to distant tumors after systemic application in murine models. 5 -7 In the present study, we have employed these gene delivery systems to target gene expression of a highly potent, yet highly toxic, molecule -tumor necrosis factor-( TNF) -to distant tumors with the aim to separate the antitumor activity of TNF from its systemic toxicity. TNF -, a pleiotropic cytokine, was originally found by its ability to induce hemorrhagic tumor necrosis and tumor regression in murine tumor models. 8, 9 Activation and damage of tumor vascular endothelium, 10 -12 activation of inflammatory and immune cells, 13 -15 and direct cytotoxic effects on tumor cells 16 are considered the main mechanisms for TNF activity in vivo. 8 -12 Although animal studies have demonstrated potent antitumor activity, the clinical application of TNF is hampered by the severe systemic toxicity including disseminated coagulopathies and capillary leakage, metabolic acidosis, acute hypotension, organ failure, and lethal shock syndrome. 17 -21 Even the design of TNF mutants with restricted activity finally did not lead to a separation of antitumor activity and systemic toxicity. 21, 22 In order to increase the antitumor effect of TNF while reducing its toxic side effects, clinical studies have employed isolated limb perfusion with TNF in combination with melphalan and interferon -. 23, 24 Whereas these studies in patients with melanoma or sarcoma of the extremities have demonstrated the therapeutic potency of TNF, systemic targeting of TNF to visceral tumor localizations or disseminated metastases remains a major challenge.
In the present study, surface -shielded Tf -PEI -based gene delivery systems were used for the first time to target gene expression of a highly potent effector molecule to distant tumors following systemic application. TNF expression localized to the tumor resulted in hemorrhagic tumor necrosis and inhibition of tumor growth without systemic TNF -related toxicity.
Materials and methods

Chemicals and expression vectors
PEI, branched, 25 kDa, and linear PEI, 22 kDa, were obtained from Aldrich ( Milwaukee, WI ) and MBI Fermentas (St. Leon -Rot, Germany ), respectively. Tf -PEI ( 25 kDa ) synthesis has been described previously. 7 The plasmids pCMVL, pCMV, and pGSmuTNF coding for luciferase, -galactosidase ( -gal ), and murine TNF, respectively, and the nonexpressing plasmid pSP65 were purified by ELIM Biopharmaceuticals ( San Francisco, CA ). Endotoxin levels were < 0.1 U / 50 g DNA as determined by Limulus Amebocyte Lysate assay ( BioWhittaker, Walkersville, MD ).
Cells and animals
Murine Neuro2A neuroblastoma cells were cultured in RPMI 1640 medium / 10% FCS. Murine M -3 melanoma cells were cultured in HAM's F10 medium /15% horse serum / 5% FCS. Murine MethA fibrosarcoma cells (kindly provided by Dr Fichtner, Max -Delbrück Center, BerlinBuch, Germany ) were passaged in vivo as intraperitoneal ascites in syngeneic BALB / c mice. A /J, DBA /2, and BALB/ c mice ( 7-8 weeks, female ) were purchased from Harlan ( Bicester, UK ).
Preparation of transfection complexes
PEI / DNA complexes were prepared as described. 7 Plasmid DNA (200 g/ mL ) was flash-mixed with PEI ( 22 kDa ) at N / P= 7 (N /P= molar ratio of PEI nitrogen to DNA phosphate ) in 20 mM HEPES ( pH = 7.3). For isoosmolarity, glucose was added to a final concentration of 5% (wt /vol ). The potential of transfection complexes was measured using a Malvern Zetasizer 3000 as described previously. 6 Tf -PEI /DNA complexes were prepared as described previously 7 by flash mixing of DNA (200 g/ mL ) with the polycation solution (containing three parts PEI and one part Tf -PEI ) at N /P=4.8. Complexes were prepared in 20 mM HEPES (pH =7.3 )/5% glucose or 0.5Â HBS (75 mM NaCl, 20 mM HEPES, pH = 7.3) /2.5% glucose.
Determination of luciferase reporter gene expression after systemic application
A / J mice were injected subcutaneously with 1Â10 6 Neuro2a cells. After 2 weeks, tumors had reached 10 -13 mm in size; transfection complexes ( 250 L / mouse ) with the pCMVL plasmid were injected into the tail vein. Animals were sacrificed by cervical dislocation at indicated time points. Organs were resected, homogenized in 250 mM TRIS buffer, pH 7.5, using an IKA Homogenizer, frozen in liquid nitrogen, and stored at À 808C. Luciferase activity in the tissue lysate was measured using a Lumat LB9507 instrument ( Berthold, Bad Wildbad, Germany ) as described previously. 5 Luciferase background ( 100-200 RLU ) was substracted from each value and transfection efficacy is expressed as RLU (relative light units) per organ. One million RLU correspond to 2 ng of luciferase.
Determination of TNF gene expression after systemic application
Neuro2a tumor-bearing A / J mice were injected into the tail vein with transfection complexes (250 L /mouse ) containing an expression plasmid for murine TNF or -gal. At indicated time points (e.g., 24 and 48 hours ) after injection of transfection complexes, blood was taken, the animals were sacrificed, and the organs were resected, homogenized, frozen in liquid nitrogen, and stored at À 808C. Blood samples were allowed to clot for 1 hour at RT and the serum was snap -frozen and stored at À 808C. TNF levels in the tissues or serum were measured by ELISA for murine TNF ( R&D Systems, Minneapolis, MN ).
Therapeutic models
A /J mice were injected subcutaneously with 1Â10 6 syngeneic Neuro2a tumor cells, DBA /2 mice were injected with 1Â10 6 M-3 cells, and BALB /c mice were injected with 2Â10 6 MethA cells. Starting at indicated time points after tumor setting ( tumor diameter, 5 -8 mm ), transfection complexes containing the plasmid for murine TNF, for a control plasmid for -gal, or the nonexpressing pSP65 plasmid were injected into the tail vein. Tumor size and body weight of the animals were monitored. Differences in tumor growth were statistically analyzed using one -way ANOVA ( tumor growth ) and contingency tables (tumor necrosis, complete tumor regression ) analyzed by Chi -square test and Fisher's exact test, using GraphPad Prism 2 software.
Histology
For immunohistological staining, cryosections ( $7 m) on microslides were fixed in cold acetone. Endogenous peroxidase was quenched by incubating the slides in hydrogen peroxide (Sigma, St. Louis, MO; 0.03% in PBS ), slides were blocked with 1% BSA for 15 minutes, with 10% goat serum for 15 minutes, and subsequently with DAKO Biotin Blocking System ( DAKO, Carpintera, CA ). Following incubation with either rat anti -mouse macrophage F4 /80 mAb (Clone Cl:A3 -1, 10 g /mL; Serotec, Oxford, UK ) or rat anti -mouse CD11b mAb ( Clone M1 /70, 6.25 g/mL; Pharmingen, San Diego, CA ), detection was performed with diaminobenzidine ( DAB ) using a Anti -Rat IgG HRP Detection kit ( Pharmingen ) according to the manufacturer's instructions. Hematoxylin (Merck, Vienna, Austria ) staining was done using a standard procedure. Slides were mounted with Entellan new medium ( Merck ) and evaluated under an Olympus ( Vienna, Austria) BH -2 microscope equipped with an Olympus DP12 camera.
Results
Surface -shielded polycation / DNA complexes for tumor -targeted gene delivery
Positively charged polycations, such as low -molecularweight PEIs ( e.g., branched PEI, 25 kDa; linear PEI, 22 kDa ), can condense DNA and have shown promising transfection efficacy in cell culture and in vivo applications. 4, 25 As previously shown, systemic application of linear
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Tumor-targeted TNF gene delivery R Kircheis et al PEI22/ DNA complexes results in particularly high reporter gene expression in the lungs and significant expression in other organs. 25 By modification of PEI /DNA complexes by covalent coupling of transferrin to the PEI backbone, we have recently developed surface-shielded Tf-PEI -based gene delivery systems, which are able to target gene expression to distant tumors after systemic application. 7 To demonstrate targeted versus nontargeted gene delivery to subcutaneously growing Neuro2a tumors, surface -shielded Tf -PEI /PEI /DNA complexes ( potential: +7 mV ) or positively charged PEI22 /DNA complexes ( potential: + 30 mV ) coding for the luciferase reporter gene were applied systemically into the tail vein of A /J mice. An unspecific expression profile with high luciferase expression in the lungs and other major organs was observed with PEI22/ DNA complexes ( Fig 1A ) . In contrast, surfaceshielded Tf -PEI / PEI /DNA complexes resulted in specific expression in the tumor, whereas expression in the lungs and other organs was dramatically reduced (Fig 1B ) . The kinetics of luciferase reporter gene expression was measured following single or repeated application of surface -shielded Tf -PEI /PEI /DNA complexes in the tail vein of tumorbearing mice. Gene expression was transient, with the single application showing a peak at 48 hours, thereafter decreasing to very low expression levels at day 4, and no luciferase activity was detectable at day 7. Repeated application ( days 0 and 1 ) resulted in higher expression levels at all time points, and significant luciferase activity was still detectable in the tumor 1 week after application ( Fig 1C ) .
Localization of TNF activity to the tumor
The aim of this study was to target gene expression of the highly potent cytokine TNF to the tumor in order to reduce the systemic toxicity observed with systemic application of TNF. Using nontargeted PEI22/ DNA[ TNF] complexes resulted in an unspecific gene expression pattern with highest TNF expression detected in the lungs, followed by the liver, heart, and tumor. Moreover, application of PEI22/ DNA[ TNF] complexes was associated with significant TNF serum levels (Fig 2A ) . In control animals receiving similar PEI22 /DNA complexes with the -gal reporter gene instead of the TNF gene, no significant TNF levels were found ( data not shown). In contrast, application of surface -shielded Tf -PEI /PEI /DNA[TNF ] complexes resulted in predominant TNF levels in the tumor. Lower TNF levels were found in liver and spleen. Importantly, no significant TNF levels were observed in the serum ( Fig  2B ) . Similarly, as found with the luciferase reporter gene ( Fig 1C ) , also TNF expression was transient with peak levels in the tumor 48 hours after application of surfaceshielded Tf -PEI / PEI /DNA[TNF ] complexes (Fig 2B,  insert) followed by a rapid decrease indicating the need for repeated application. In comparison, TNF expression after application of nonshielded PEI22/ DNA[ TNF] complexes was even shorter with peak levels in the lungs and serum 24 hours after application, followed by a rapid decrease ( Fig 2A, insert ) .
To test the biological effects of targeted TNF gene therapy, Neuro2a tumor-bearing A /J mice were injected with shielded Tf -PEI /PEI / DNA[ TNF] or nonshielded PEI / DNA[ TNF] complexes. Complexes were applied repeatedly at indicated time points into the tail vein. Control animals were left untreated or injected with complexes having the empty plasmid vector pSP65. Body weight of the animals, as an indicator of TNF toxicity, was monitored Figure 1 Gene delivery with different types of transfection complexes. Nontargeted PEI22 / DNA ( A ) or targeted Tf -PEI / PEI / DNA complexes ( B ) containing the pCMVL plasmid were injected into the tail vein of Neuro2a tumor -bearing mice. Luciferase activity ( RLU / organ; mean ± SD ) was measured 24 hours after injection. C: Kinetics of gene expression after systemic application of targeted Tf -PEI / PEI / DNA complexes. Transfection complexes containing 50 g of DNA were injected once ( day 0 ) or twice ( days 0 and 1 ). Luciferase reporter gene expression was measured at indicated time points. Animal number was n!3 per time point.
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Tumor-targeted TNF gene delivery R Kircheis et al during treatment (Fig 2, C and D ) . A significant drop in body weight of 10% was found with nonshielded PEI / DNA[TNF ] complexes after the first two applications ( P <.05, TNF versus control ) ( Fig 2C ) . There was no further weight loss after the following applications; however, in one out of two experiments, nonshielded PEI /DNA [ TNF] complexes resulted in the death of 2 /8 animals. In contrast, only a slight body weight loss was found with shielded Tf-PEI /PEI / DNA[ TNF] complexes ( Fig 2D ) or with shielded or nonshielded complexes containing pSP65 ( Fig 2, C and D ) . Importantly, all eight applications of shielded Tf -PEI / PEI /DNA[TNF ] complexes were well tolerated by the animals.
Comparing the antitumor activity, significant inhibition of tumor growth was observed with targeted Tf -PEI /PEI / DNA[TNF ] complexes (P < .01, TNF versus untreated control or pSP65-treated animals ) (Fig 2F ) . Nontargeted PEI /DNA[ TNF] complexes also inhibited tumor growth ( P <.05, TNF versus untreated control ) (Fig 2E) , however, to a lesser extent compared to the targeted complexes ( P <.05, targeted TNF versus nontargeted TNF). Complexes with the pSP65 control plasmid did not significantly inhibit tumor growth; similar results were observed with additional control complexes with the -gal reporter gene ( data not shown ).
The predominant TNF expression in the tumor found with targeted Tf-PEI /PEI / DNA[ TNF] complexes, together with absence of detectable TNF serum levels, good biocompatibility, and higher antitumor activity -in comparison to the unspecific expression pattern of nonshielded PEI /DNA[TNF ], which was associated with significant TNF serum levels, and induction of body weight loss and systemic toxicity -clearly indicated that the targeted transfection complexes may be better suited for systemic gene delivery of the highly potent TNF to distant tumors. In all further experiments, therefore, systemic application of targeted Tf -PEI /PEI /DNA[TNF] was used.
The most striking effect of the TNF gene therapy was the induction of hemorrhagic tumor necrosis ( Fig 3, A and B ) . More than 80% of the TNF-treated animals developed hemorrhagic tumor necroses, whereas hemorrhagic tumor necrosis was virtually not found in control animals ( P < .01, TNF versus control ) and only rarely found in pSP65-orgal -treated animals (P < .01, TNF versus -gal or pSP65) ( Fig 3C ) . Necrosis was most pronounced in the center of the tumor. However, there was only in very few cases a complete eradication of the tumor in this model. After cessation of treatment, tumor cells located outside of the necrotic areas started to regrow. The therapeutic efficacy of targeted TNF gene delivery correlated with the number of applications. Pre-experiments on a small number of animals with single application showed only moderate therapeutic effect and high variability among the animals not allowing significant conclusions (data not shown ). To compare the therapeutic efficacy of different treatment regimes, the T / C ratio (tumor growth in treated group compared to control group ) was measured after different numbers of applications. A ratio of T / C <50% is generally considered indicative for a significant therapeutic effect. Four applications of TNF gene therapy showed a significant therapeutic effect with a ratio of T /C =32%; however, there was a variability in the treatment group. Six or eight applications of targeted TNF gene transfer complexes resulted in a T / C ratio of 25% or 13%, respectively, indicating higher efficacy with higher number of applications. Furthermore, increasing the number of application also minimized the variability among the animals in the treatment groups ( Fig 3D ) . Further experiments demonstrated that hemorrhagic tumor necrosis and inhibition of tumor growth were induced only by transfection complexes coding for TNF, whereas cytokines with a more indirect immune -mediated mechanism of action, such as interleukin -2 or interferon-, did not show significant efficacy in this aggressive tumor model (data not shown).
Tumor -targeted TNF gene delivery to melanoma and fibrosarcoma
We tested targeted TNF gene delivery in two other tumor models, the murine M-3 melanoma and the MethA fibrosarcoma (Fig 4 ) . DBA /2 mice bearing subcutaneously Macroscopically visible hemorrhagic tumor necrosis was seen in some of the animals (4 /18), and significant inhibition in tumor growth was observed in all animals ( P <.01, TNF versus untreated control or -gal-treated animals ) ( Fig 4A ) . In the second model, BALB/ c mice bearing subcutaneously growing MethA fibrosarcomas were injected similarly with targeted complexes containing the TNF gene or the -gal reporter gene as a control. Systemic application of transfection complexes coding for TNF resulted in an inhibition in tumor growth, in comparison to untreated animals or control animals treated with complexes coding for -gal (Fig 4B ) . Similarly, as in the Neuro2a tumor, also in the MethA model -pronounced hemorrhagic tumor necrosis was observed in the majority of the animals treated with TNF coding transfection complexes. Figure 5A shows a representative picture of a necrotized tumor 2 days after the treatment course of four applications of TNF transfection complexes into the tail vein. Representative tumors of -gal -treated animals or untreated control animals are shown in Figure 5 , B and C, respectively. Furthermore, the hemorrhagic tumor necrosis induced by TNF transfection frequently resulted in complete tumor regression, which was found in more than 60% of the Tumor size was monitored. *P < .01, TNF versus -gal and control; n = 10.
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Tumor-targeted TNF gene delivery R Kircheis et al animals 2 weeks after TNF treatment ( Fig 5D ) . All animals that developed complete tumor regression were also protected from rechallenge with a tumorigenic dose of 2Â10 6 MethA tumor cells ( data not shown ). Occasionally, tumor regression was observed in untreated animals due to the immunogenicity of MethA. A summary of the frequencies of complete tumor regression from two experiments is given in Figure 5G , showing a significant difference between TNF -treated animals and control animals ( P <.05, TNF versus untreated control ). Interestingly, application of transfection complexes coding for -gal resulted in tumor regression in one third of the animals pointing to a certain degree of unspecific antitumor activity of the transfection complexes, 26 although this effect was not significant (not significant, -gal versus untreated control ), in contrast to TNF transfection complexes (P < .05, TNF versus untreated control ). However, the most striking effect was the TNF -induced hemorrhagic tumor necrosis found in almost 60% of the TNF -treated animals compared to -gal -treated or untreated animals (P < .01, TNF versus untreated control; P <.05, TNF versus -gal -treated animals) (Fig 5G ) .
Histology of tumors after targeted TNF gene delivery
The macroscopically visible morphological effects on the tumor observed after tumor-targeted TNF gene delivery ( see also Fig 3A ) correlated with pronounced changes in the histology of the tumors ( Fig 6) . After four applications of and detected with a streptavidin -HRP / DAB system and evaluated under an Olympus BH -2 microscope equipped with an Olympus DP12 CCD camera. Magnification, Â40 ( A,B ), Â400 ( C ), Â1000 ( B, insert ).
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Tumor-targeted TNF gene delivery R Kircheis et al TNF coding transfection complexes, the histology of Neuro2a tumors showed large areas of tissue necrosis. These areas appeared largely devoid of the normal structure characteristic for this tumor due to intensive necrosis with some structures of stroma, infiltrating macrophages (Fig 6B,  insert) , and few picnotic tumor cells remaining. Necrotic areas were surrounded by areas that were heavily infiltrated by F4 /80 and CD11b + macrophages (Fig 6, B and C ) . Other inflammatory cells such as lymphocytes (CD4 /CD8 staining ) or granulocytes were only sparsely observed (data not shown). The histological findings in the tumor following tumor-targeted TNF gene delivery resembled the histological changes described for TNF protein application. 12 However, in contrast to the major systemic toxic effects after TNF protein application, 12,17 -22 no significant morphological and histological changes were found in major organs including heart, liver, lungs, spleen, and kidney in animals treated with targeted TNF gene therapy.
Discussion
An effective antitumor therapy has to combine efficacy against the tumor with lowest possible effects on normal tissues and organs. This ratio of antitumor activity to systemic toxicity is most relevant for highly potent biomolecules, such as TNF or related cytokines including TNF, IL -1, or IL -6. These cytokines show pronounced biological effects even at low doses, with a broad target spectrum. 9, 15, 17, 18, 21, 27 Whereas animal studies demonstrated impressive hemorrhagic tumor necrosis in a variety of tumor models, clinical studies with systemic TNF protein therapy of cancer patients showed only marginal therapeutic effects, but high systemic toxicity. 28 -30 The major problem is that both antitumor activity and acute TNF-induced toxicities are based on similar pathophysiological mechanisms, i.e., activation of the endothelial cells and inflammatory cells, changes in coagulation and fibrinolytic systems, disturbances of microcirculation, and capillary leakage. 9 -14 Whereas inflammatory reactions and hemorrhagic tumor necrosis are localized, a systemic release of high amounts of TNF can lead to life -threatening symptoms including hypotension, organ failure, and metabolic acidosis, which can result in lethal shock syndrome. 15,17 -21,28 -30 The only practicable possibility for segregation of antitumor activity and systemic toxicity is the localization of TNF activity specifically to the tumor.
The focus of the present study was to target TNF activity to the tumor following systemic application using tumortargeted delivery of the TNF gene, which could present a new modality for treatment of metastatic tumor disease. Approaches using the TNF gene for antitumor therapy instead of the protein have been shown recently by using locoregional application into the arteries leading to the tumor 31 or intratumoral application. 32 However, targeting the TNF gene to tumor sites that are not directly accessible or to disseminated metastases is still a major challenge. We have developed tumor-targeted gene delivery systems as the technological platform to target TNF activity. The DNA is shielded from nonspecific interactions with plasma proteins and nontarget cells, resulting in prolonged blood circulation and passive extravasation 5 -7 in areas of increased vascular leakiness such as tumors. 33 -36 Furthermore, ligands like transferrin give the possibility of active targeting to the respective receptor on the tumor cells. 37, 38 Targeting TNF activity using surface -shielded DNA complexes resulted in significant TNF gene expression within the tumor without detectable serum levels. In contrast, nonshielded complexes resulted in an unspecific TNF expression pattern and significant TNF serum levels associated with significant body weight loss, proving to be not suitable for targetspecific gene delivery to distant tumors. With targeted TNF complexes, hemorrhagic tumor necrosis and inhibition of tumor growth were demonstrated in three tumor models of different tissue origin such as neuroblastoma, melanoma, and fibrosarcoma. Using this technology, we have focused TNF gene expression within the tumor, leading to therapeutic effects while reducing the systemic toxicity that is usually associated with systemic TNF protein therapy. This technology has the potential to target multiple metastatic nodules disseminated throughout the body. However, complete tumor regressions were found only in one model. This may be due to the fact that the efficacy of nonviral gene delivery systems in general still needs further optimization. Due to the transient expression pattern and the relatively low expression levels, repeated applications were necessary for a maximal therapeutic effect. A further option to increase the therapeutic efficacy might be the combination of TNF gene therapy with established anticancer treatments, such as chemotherapy or irradiation.
In summary, these studies provide a proof of principle that targeted gene delivery to tumors may be an attractive strategy applicable to TNF and other highly active, yet toxic, molecules in cancer treatment.
